In Piedmont's Alessandria province, the cortese grape flourishes, creating the renowned Gavi wine. Amid summer breezes and lush vineyards, boutique winery La Chiara offers a taste of coastal ...

Bad news for Novo Nordisk (NVO 2.14%) Friday was good news for Eli Lilly (LLY 0.25%) and Viking Therapeutics (VKTX 2.74%), its two main rivals in the field of weight loss drugs. This morning ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss targeted by executives, prompting investors to wipe 19% off the value ...

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management, leading to a 20% stock decline. CagriSema may still be competitive to ...

Lamine Yamal and Gavi Páez scored to lead Barcelona past Athletic Club 2-0 and into the Spanish Super Cup final on Wednesday. Gavi scored in the 17th minute of the semifinal for his first goal ...

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company's experimental weight-loss drug shed many fewer pounds than expected. Specifically, the weight of patients ...

Novo Nordisk has announced its latest trial result for the new obesity drug, CagriSema, which disappointed investors and sent its share price plunging 20% in Denmark on Friday, the sharpest one ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

Shares in Novo Nordisk plunged 20% on Friday. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and ...

LONDON/COPENHAGEN (Reuters) -Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion ...